TABLE 3.

Estimated prevalences of ARV TF in plasma, DBS, and DPS using the CAP/CTM

Reason for VL testing and ARV TF diagnostic threshold used	Prevalence (95% CI) of TF with:			P valuea
	Plasmab	DBSc	DPSd	Plasma-DBS	Plasma-DPS
Overall
5,000 copies/ml	0.18 (0.16–0.21)	0.55 (0.51–0.58)	0.19 (0.16–0.23)	<.001	0.38
1,000 copies/ml	0.23 (0.21–0.26)	0.80 (0.77–0.83)	0.27 (0.23–0.31)	<.001	0.71
Routine
5,000 copies/ml	0.18 (0.15–0.22)	0.51 (0.47–0.56)	0.18 (0.14–0.22)	<.001	0.21
1,000 copies/ml	0.22 (0.18–0.25)	0.80 (0.76–0.82)	0.25 (0.20–0.30)	<.001	0.28
Targeted
5,000 copies/ml	0.18 (0.14–0.22)	0.58 (0.53–0.64)	0.21 (0.16–0.26)	<.001	1
1,000 copies/ml	0.25 (0.21–0.30)	81.5 (0.77–0.86)	0.30 (0.24–0.35)	<.001	1

^aDifference between prevalence estimates in plasma-DBS or plasma-DPS pairs tested for significance using McNemar's test for paired proportions.

^bn = 838.

^cn = 823.

^dn = 546.